Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 4Sarcoma 1Head & Neck 1Endocrine 1

Conditions

Parathyroid Neoplasms 1Multiple Endocrine Neoplasia 1Hypoglycemia 1Hyperparathyroidism 1Hypercalcemia 1

Interventions

Cisplatin 136Cetuximab 101pembrolizumab 83Radiotherapy 62Carboplatin 57Radiotherapy, Intensity-Modulated 54Fluorouracil 47Docetaxel 47Nivolumab 44Paclitaxel 37Radiation 21Erlotinib Hydrochloride 19durvalumab 18Platinum 15Ipilimumab 14Gemcitabine 13lenvatinib 12Drug Therapy 12Bevacizumab 12Albumin-Bound Paclitaxel 12vandetanib 11Pemetrexed 11Magnetic Resonance Spectroscopy 111,2-diaminocyclohexaneplatinum II citrate 11Radiosurgery 10Everolimus 10tremelimumab 9epacadostat 9Surgical Procedures, Operative 9Sorafenib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × fluorodopa F 18 × Head & Neck × Clear all
NCT00001277 2022-06-07

Studies of Elevated Parathyroid Activity

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
1,553 enrolled 8 charts
EndocrineHead & Neck

Hypercalcemia, Hyperparathyroidism, Hypoglycemia, Multiple Endocrine Neoplasia, Parathyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡